Efficacy and Safety Evaluation of Hemoglobin Control by Erythrocyte Stimulate Agent Recommendation Algorithm in Kidney Failure with Renal Replacement Therapy: Multicenter, Prospective, Single Blind, Randomization Control Trials

Yonsei University Health System, Severance Hospital0 个研究点目标入组 250 人开始时间: 待定最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•Patients with end-stage renal disease who have been on hemodialysis for more than 6 months
•- Patients with hemoglobin levels above 8.0 g/dL and below 14.0 g/dL
•- Patients using or planning to use Darbepoetin alpha
•- Adults over 19 years old and under 80 years old
•- Patients weighing more than 40.0 kg and less than 100.0 kg
•- Among the target subjects, patients whose voluntary consent procedure was confirmed after explanation of the clinical trial
•- Patients who can collect clinical variables for the past 5 months from the time of study registration required for algorithm operation

•- Patients temporarily receiving hemodialysis due to acute kidney disease
•- Patients temporarily undergoing hemodialysis before transplantation
•- Patients who have experienced blood transfusion within 3 months of participating in the study
•- Patients with serious systemic condition
•- Patients with low compliance, e.g., people with mental illness
•- Patients withdrew from clinical trials

发起方